Because ARID1A inactivation is frequently found in pancreatic cancer, the identification of vulnerable genes in ARID1A‐deficient pancreatic cancer by using different experimental approaches has been intensively performed in recent years and several dysregulated pathways have been suggested to be potential therapeutic targets. Here, ARID1A is linked to familial pancreatic carcinoma.